Abstract Details

Title Modified Ketogenic Diet Therapy for Relapsing Multiple Sclerosis: Patient-Reported Outcomes

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-044

Objective To report the multiple sclerosis (MS) patient experience after completion of a 6 month trial of a modified ketogenic diet.

Background Dietary intake influences an individual’s immune profile and response. The impact of diet in MS is clinically meaningful, with evidence supporting an association between diet and disability. We have previously reported evidence of safety and adherence of ketogenic diets (KDs) in relapsing-remitting MS (RRMS) patients, with improvements in fatigue, depression, and disability metrics.

Design/Methods Twenty patients with a diagnosis of RRMS were enrolled. Subjects were educated in-person by a trained dietitian on how to adhere to a modified KD (i.e. modified Atkins or KD^MAD). Adherence to diet was objectively monitored by daily urine ketone testing. Clinical and patient-reported outcome measures were obtained at baseline (pre-diet) and after 6 months of treatment. A patient-experience survey was completed at the time of diet trial completion.

Results Of the 20 subjects enrolled at baseline, two subjects were lost to follow-up. From the remaining 18 subjects, over half had previously attempted a diet for their MS. Upon completing the 6 month trial of KD^MAD, 56% of subjects planned to continue on strict KD^MAD after trial completion. All 18 subjects would recommend KD^MAD to a colleague. The most common patient-perceived benefits of KD^MAD included weight loss (83%), improved fatigue (72%), improved exercise habits (55.5%), improved stamina (50%), and reduced MS symptoms (45%). The most common side effects experienced on KD^MAD included constipation (28%), menstrual irregularities (22%), and diarrhea (17%).

Conclusions

The KD^MAD is a feasible diet for RRMS patients and provides multiple patient-perceived benefits that are clinically-relevant to MS subjects. As the majority of our subjects plan to continue on KD^MAD, longitudinal clinical and laboratory data collection is ongoing.

Authors/Disclosures
James N. Brenton, MD, FAAN PRESENTER	Dr. Brenton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for I-ACT on a Novartis sponsored project. The institution of Dr. Brenton has received research support from NIH/NINDS. The institution of Dr. Brenton has received research support from Autoimmune Encephalitis Alliance. Dr. Brenton has received publishing royalties from a publication relating to health care. Dr. Brenton has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Department of Defense. Dr. Brenton has received personal compensation in the range of $0-$499 for serving as a Grant Reviewer with NIH. Dr. Brenton has received personal compensation in the range of $0-$499 for serving as a Grant Reviewer with FDA.
Brenda L. Banwell, MD, FAAN (Johns Hopkins University)	Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.
A. G. C. Bergqvist, MD (The Children's Hospital of Philadelphia)	Dr. Bergqvist has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Myla D. Goldman, MD, MSc, FAAN (Virginia Commonwealth University)	Dr. Goldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentec. Dr. Goldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Immunic. Dr. Goldman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis Pharmceuticals. Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniska. Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Brainstorm Cell Therapeutics Ltd., . Dr. Goldman has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. Dr. Goldman has received personal compensation in the range of $0-$499 for serving as a Grant Review Committee Member with Department of Defense.

��ɫ��

��ɫ��